WallStreetZenWallStreetZen

NASDAQ: NRSN
Neurosense Therapeutics Ltd Stock

$1.17+0.01 (+0.86%)
Updated May 24, 2024
NRSN Price
$1.17
Fair Value Price
$0.19
Market Cap
$17.95M
52 Week Low
$0.40
52 Week High
$2.33
P/E
-1.41x
P/B
-9.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.7
Operating Cash Flow
-$8M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NRSN Overview

NeuroSense Therapeutics Ltd. is developing treatment for patients with debilitating neurodegenerative diseases.The company's lead product, PrimeC, is a novel oral formulation in clinical trials to treat amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease, and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics was incorporated in 2017 and is headquartered in Herzliya, Israel.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NRSN ($1.17) is overvalued by 527.19% relative to our estimate of its Fair Value price of $0.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NRSN ($1.17) is not significantly undervalued (527.19%) relative to our estimate of its Fair Value price of $0.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRSN due diligence checks available for Premium users.

Be the first to know about important NRSN news, forecast changes, insider trades & much more!

NRSN News

Valuation

NRSN fair value

Fair Value of NRSN stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$0.19
Overvalued by
528.80%
NRSN ($1.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRSN ($1.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NRSN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.41x
Industry
15.58x
Market
32.03x

NRSN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-9.58x
Industry
6.08x

NRSN's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
NRSN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.2M
Liabilities
$5.1M
Debt to equity
-2.7
NRSN's short-term liabilities ($3.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRSN's short-term assets ($2.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
NRSN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NRSN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NRSN$17.95M+0.60%-1.41x-9.58x
APTO$18.10M+2.78%-0.18x132.14x
PMCB$18.11M0.00%-1.78x0.58x
TCRT$18.41M+6.48%-0.62x3.84x
GLYC$17.41M-1.10%-0.47x0.60x

Neurosense Therapeutics Stock FAQ

What is Neurosense Therapeutics's quote symbol?

(NASDAQ: NRSN) Neurosense Therapeutics trades on the NASDAQ under the ticker symbol NRSN. Neurosense Therapeutics stock quotes can also be displayed as NASDAQ: NRSN.

If you're new to stock investing, here's how to buy Neurosense Therapeutics stock.

What is the 52 week high and low for Neurosense Therapeutics (NASDAQ: NRSN)?

(NASDAQ: NRSN) Neurosense Therapeutics's 52-week high was $2.33, and its 52-week low was $0.40. It is currently -49.91% from its 52-week high and 191.75% from its 52-week low.

How much is Neurosense Therapeutics stock worth today?

(NASDAQ: NRSN) Neurosense Therapeutics currently has 15,379,042 outstanding shares. With Neurosense Therapeutics stock trading at $1.17 per share, the total value of Neurosense Therapeutics stock (market capitalization) is $17.95M.

Neurosense Therapeutics stock was originally listed at a price of $4.04 in Dec 9, 2021. If you had invested in Neurosense Therapeutics stock at $4.04, your return over the last 2 years would have been -71.11%, for an annualized return of -46.25% (not including any dividends or dividend reinvestments).

How much is Neurosense Therapeutics's stock price per share?

(NASDAQ: NRSN) Neurosense Therapeutics stock price per share is $1.17 today (as of May 24, 2024).

What is Neurosense Therapeutics's Market Cap?

(NASDAQ: NRSN) Neurosense Therapeutics's market cap is $17.95M, as of May 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neurosense Therapeutics's market cap is calculated by multiplying NRSN's current stock price of $1.17 by NRSN's total outstanding shares of 15,379,042.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.